Purple Biotech Ltd. · TASE:PPBT
Purple Biotech — Investor Presentation (September 2021)
37 slides from Purple Biotech's investor presentation, Sep 13, 2021
Slide 1: Corporate Presentation
CORPORATE PRESENTATION © YASDAQ/TASE: September 2021
Slide 2: Forward-looking Statements and Safe Harbor
Forward-looking Statements and Safe Harbor Certain statements in this presentation that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Such forward-look
Slide 3: Business Highlights
Business Highlights C24 - First-in-class a-CEACAM1 mAb, validating Strong balance sheet and clinical collaboration with Bristol Myers Squibb cash position Purple Biotech (NASDAQ/TASE: PPBT) NT219 - First-in-class, small molecule, dual ADSs outstanding: 17.5M inhibitor of IRS 1/2 and STAT3 $53M cash
Slide 4: Advancing Clinical-stage Novel Oncology Therapies
Advancing Clinical-stage Novel Oncology Therapies Program Indication Preclinical Phase! Phase2 Phase3 Partner —-Value Drivers Solid tumors (monotherapy) L__ > (Completed) Solid tumors (combination with. Expansion arms on nivolumab) RP2D: Initiation Q4:21 Bristol Myers Squibb NSCLC (combination with
Slide 5: Experienced Leadership
Experienced Leadership AMGEN * Biogen @xkamava Isaac Israel Chief Executive Officer Former CEO of BeeContact Ltd. (TASE:BCNT). NextGen Biomed (TASE: NXGN) Gil Efron Deputy CEO and Chief Financial Officer Former Deputy CEO & CFO at Kamada (NASDAQ:KMDA) Bertrand Liang, MD, Ph.D, MBA/AMP, FAAN Chief Me
Slide 6: Advancing First-in-Class Oncology Therapies: CM24
Advancing First-in-Class Oncology Therapies CM24 - an a-CEACAMI mAb
Slide 7: CEACAM1 Plays a Key Role in Cancer Biology
CEACAMI' Plays a I|<ey Role in Cancer Biology O1| ADHESION Horst, 2011 Oncogene “CEACAMI creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation” @ Fare ogy “Neutrophil extracellular trap- associated CEACAM1 as a putative Hieei oh ea carcinoma” O02] IMMUNE CELLS/ IMMUNE
Slide 8: CM24 MOA | Immuno-oncology
CM24 MOA | Immuno-oncology Tumor cell or pAPC Tumor CEACAMI CEACAMA CEACAMS. e. a cpas/148 3) eK Wy GPaR ee o)- he CEACAM: ceAcAML * pe z (CDB+T & NK Cells v Activation enhanced cytotoxic activity & cytokine production ‘Markel et oJ immunel 2002, 2006; immunology, 2008; Cancer Immunel Immunother 201
Slide 9: CM24 MOA | Adhesion
CM24 MOA | Adhesion Neutrophil extracellular trap-associated CEACAMI1 as a putative therapeutic target to prevent metastatic progression: Primary Tumor Metastasizing CEACAMI creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. CM24 is proposed to attenuate/block tum
Slide 10: Anti-cancer Effect Following Treatment
Anti-cancer Effect Following Treatment Preclinical Data With CM24 + TIL and CM24 + a-PDI1 TIL + IgG TIL+ M24 Bo Naive =e * Xenograft, lung lesion, Mel 526 (IV) Combination index (Cl) = 0.15 + Tumor burden was monitored 26 days post last CM24 ©: Or» treatment I=, * Dp < 1 > synergy & Significant bene
Slide 11: CM24 Phase 1 Monotherapy Trial
CM24 Phase 1 Monotherapy Trial UCLA NO ‘issmat # pts + Open-label, multi-dose escalation 27 patients: o1me/ke @ monotherapy study to assess safety and 2 tolerability Gleese) ath 0.03me/kg @ * Heavily pre-treated patients with a median Melanoma 7. of 4 prior regimens (range 2-8) Overall, Ovarian 4 0.
Slide 12: PK/PD Modeling Provides Dosage & Schedule Guidance
PI</PD Modeling Provides Dosage & Schedule Guidance Simulated TMDD" saturation at Ctrough * Consistent with observed PK showing high with Q2W regimen clearance at doses <10 mg/kg, plot shows low [roo —_— > TMDD saturation at low doses * 10 mg/kg has a broad range of saturation, and >10 mg/kg, Q2W do
Slide 13: Large Market Opportunity in NSCLC & Pancreatic Cancer
Large Market Opportunity in NSCLC & Pancreatic Cancer + Pancreatic Cancer accounts for ~60K new cases/year in the US; with a 5-year relative survival rate of 10%? + I/O approaches have been limited to patients with high microsatellite instability (MSI-H) or high tumor mutational burden (TMB-H) * 5-y
Slide 14: CM24 Phase 1/2 Combination Study Design
CM24 Phase 1/2 Combination Study Design (NCTO4731 A Phase 1/2 open label multi center study of CM24 in combination with: + Nivolumab in selected cancer indications (Phase 1) and NSCLC (Phase 2) * Nivolumab and nab-paclitaxel in pancreatic cancer (Phase 2) 2021 Dose Escalation Doses: 10, 15, 20mg/kg
Slide 15: 1st Cohort Analysis - Safety and Response
1st Cohort Analysis - SAFETY and RESPONSE 10mg/kg Dose Level in combination with nivolumab * The administration of CM24 at 10mg/kg q2wks in combination with nivolumab at 480mg q4wks was well tolerated with no SAEs in patients with refractory PDAC ¢ Three patients were enrolled into the first dose co
Slide 16: Advancing First-in-Class Oncology Therapies: NT219
Advancing First-in-Class Oncology Therapies NT219 - A Small Molecule Dual Inhibitor of IRS 1/2 and STAT3
Slide 17: NT219 - Dual Inhibitor of IRS1/2 & STAT3
NT219 - Dual Inhibitor of IRS1/2 & STAT3 IRSI/2 + Scaffold proteins, mediating mitogenic, metastatic, angiogenic and anti- apoptotic signals from IGF1R, IR, IL4R and other oncogenes, overexpressed in multiple tumor types STAT3 * Regulates major survival pathways + Well-established transcription such
Slide 18: Novel MOA: IRS Degradation By NT219
Novel MOA: IRS Degradation By NT219 Blocking IGFIR-AKT Pathway! ‘ SURVIVAL APOPTOSIS Covalent binding to IRS1/2 leads to the Serine phosphorylation prevents 1RS1/2 is degraded by the dissociation of IRS1/2 from IGF1R re-binding of IRS1/2 to the receptor proteasome @ v eiesoncinse
Slide 19: NT219 Efficacy as Monotherapy
NT219 Efficacy as Monotherapy -ecenel es) 3,000 5 ~=Cetuximab (n=5) Animal model Head & Neck Cancer 2,000 (SCC-9) NSG™, PBMCs- injected? Drugs soo | a-PD1 Cetuximab (Erbitux®) NT219 20mg/kg ° 10 20 NT219 60mg/kg —=0PD1 (n=5) e-NT219 20mg/kg (n=5) S-NT219 GOmg/kg (n=5) Tumor volume (mm*) 30 40 50 Day
Slide 20: STAT3 and IRS are Essential in Therapeutic Resistance
STAT3 and IRS are Essential in Therapeutic Resistance Blocking survival pathways MEK / ERK TUMOR REGRESSION Proof of Concept: PDX model of Head and Neck Cancer sao ar Tumor — Tumor Survival Regression Tumor Survival ‘Sunival probabil (%) 100 Control n=6) Erlotnib(r=8) Erlotinib+NT229 (n=6) — Etlotin
Slide 21: NT219 + Targeted Therapies Established Efficacy in PDX Models
NT219 + Targeted Therapies Established Efficacy in PDX Models NSCLC Exon 19 deletion EGFR and 790M, biopsy of bone marrow metastasis, patient previously progressed on afatinib and osimertinib 2) R/M SCCHN metastasis, patient previously progressed on chemoradiation, several chemotherapies, and pembro
Slide 22: NT219 + a-PD1 Re-sensitizes to Refractory a-PD1 Tumors
NT219 + a-PDI1 Re-sensitizes to Refractory o-PD1 Tumors PDX Model Humanized PDX of Esophagus Cancer (refractory to pembrolizumab) Drug Pembrolizumab (Keytruda®) 1200 1000 a keytruds (9-3) a keytrude +219 (3) ‘Tumor volume (mm3) Days following treatment initiation Autologous PBMCs (2.1 M/mouse) * Dou
Slide 23: First Market Opportunity
First Market Opportunity Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) Targeting the unmet medical need * 1L Standard of care has shifted from chemotherapy towards immuno- oncology + chemotherapy + < 20% of R/M SCCHN patients respond to a-PD1s + 175k new cases/year are exp
Slide 24: NT219 Monotherapy and Combination Phase 1/2 Study Design
NT219 Monotherapy and Combination Phase 1/2 Study Design (NCTO4474470) Study title Endpoints ‘A phase 1/2 study with open-label, dose escalation phase Primary endpoints: followed by single-arm expansion to assess the safety, Safety, pharmacokinetics and to determine the MTD tolerability, Pk, PD and
Slide 25: Interim Analysis - Safety and Response as a Single Agent
Interim Analysis - SAFETY and RESPONSE 3 mg/kg Dose Level as a Single Agent Response Analysis NT219 has been found to be well-tolerated with Cancer pny Treatment sass pespons minimal adverse events YES Ui viarapy puns i i a Pancreatic 3 °o * Ina patient with refractory GE junction disease, Cancer NT
Slide 26: Business Highlights
Business Highlights C24 - First-in-class a-CEACAM1 mAb, validating Strong balance sheet and clinical collaboration with Bristol Myers Squibb cash position Purple Biotech (NASDAQ/TASE: PPBT) NT219 - First-in-class, small molecule, dual ADSs outstanding: 17.5M inhibitor of IRS 1/2 and STAT3 $53M cash
Slide 27: We are committed to providing cancer patients with first-in-class therapies
Weare committed to providing cancer patients with first-in-class therapies to OVERCOME tumor drug resistance, ENHANCE treatment response and SLOW tumor progression 9
Slide 28: Thank You
THANK YOU = =~ Contact Us: ir@purple-biotech.com
Slide 29: Appendix A - CM24
Appendix A - CM24
Slide 30: Inhibition of Melanoma Growth Following CM24 and CM24 + TIL Treatment
Inhibition of Melanoma Growth Following CM24 and CM24 + TIL Treatment M24 activity is Demonstrated as Single Agent and in Combination with TILS 420 w1eG 10me/kg g 400 BL CM24 1ome/kg 2 380 OUTIL IgG 10me/kg, Em ~O-TIL+ M24 1Ome/kg a ry 38 E20 ga 3 Sw z 150 Fe o 1 ai Re oO 10 20 30 40 50 60 70 80 & T
Slide 31: Phase 1 Data: Target Saturation
PHASE 1 PIX DATA Target saturation was not reached with doses up to 1Omg/kg Predictions with Q3W regimen *!Modeling with increased interval between doses demonstrates lower TMDD at 10mg/kg dose * With Q3W, 20mg/kg dosing is not sufficient for saturation across population © [o-rmerte | [03 masts | [i
Slide 32: Appendix B - NT219
Appendix B - NT219
Slide 33: Selected Publications
Selected Publications OUCSandiew Michael Karin MDAnderson ‘Ganeer Center Menashe Bar-Eli © Targeting colorectal cancer via its microenvironment by inhibiting IGF-I receptor-insulin receptor substrate and ‘Terapautie Destruction ofnailn Receptor Subetrates for je hens nan mean Alexander Levitzki Mich
Slide 34: NT219 Suppresses B-Catenin Activity in CRC Cells and Inhibited CRC Brain Metastasis
NT219 | Suppresses -Catenin activity in CRC Cells and Inhibited CRC Brain Metastasis In Vitro In Vivo NN — 1NT219 downregulates IRS2 and suppresses the B-catenin activity CRC Cell Viability (72h) mm OMEM inal 1.5: fommitassoa 10- 7 ima ae 5 Apoiso | ee ea wrote | Bos pereerey Active =| 3 : issi3 B-C
Slide 35: Pancreatic Cancer: Anti-cancer Activity of NT219 with Gemcitabine
NT219 | Pancreatic Cancer Highly effective anti cancer ai ity exhibited by NT219 A 4 4 in combination with Gemcitabine in Combination with Gemcitabine Pancreatic cancer (Patient A) PDX Pancreatic cancer (Patient 8) PDX omcaioe Tumor volume (cm?) = i 3 E PDX model Pancreatic Cancer Drug Gemcitabine (
Slide 36: RNA Sequencing Analysis of Tumors Following Treatment
RNA Sequencing | Analysis of Tumors Following Treatment PDX model Pancreatic Cancer Drug Gemcitabine (Gemzar®) Reduced expression of IRS1, Ki67, FOXM1 & TGFb is exhibited by pancreatic cancer treated with NT219 alone and in combination with gemcitabine IRS1 Control NT219_ Gemzar_ Gemzar 4NT219 FOXM1
Slide 37: NT219 - Demographics & Safety as a Single Agent
NT219 - DEMOGRAPHICS & SAFETY 3 mg/kg Dose Level as a Single Agent Patients Demographics Summary of Adverse Events Grade Grate? Grade3 Demographics of Patients treated with NT219 3m (Events) _n itvents)_n(#Events) MEAT ESe (EE 74 (69-79) [Abdominal Pain 20) 20) Male/Female, n() 266 6R/1193.3% Atanin
Purple Biotech — Investor Presentation (September 2021) on 6ix